Skip to main content

Table 1 Patient characteristics between those undergoing ADT and no ADT

From: Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?

  

ADT Group

No ADT Group

 

Number (%)

Number (%)

Ethnic group

Caucasian associated

68 (90 · 7)

124 (94 · 7)

p = 0 · 3883

Māori, Pacific &East Asian

7 (9 · 3)

7 (5 · 3)

Alcohol intake

No

39 (52 · 0)

43 (32 · 8)

p =0·0079  

Yes

36 (48 · 0)

88 (67 · 2)

Smoking status

Never

31 (41 · 3)

65 (49 · 6)

p = 0·5067

Past

41 (54 · 7)

62 (47 · 3)

Current

3 (4 · 0)

4 (3 · 0)

Comorbidities

CVD

39 (52·0)

36 (48·0)

p = 1·000

 

No CVD

68 (48·0)

63 (48·0)

 
 

Total comorbidities

50 (66·7)

79 (60·3)

P = (0·3744)

 

No comorbidities

25 (33·3)

52 (39·7)

 

Clinical data

    

Gleason score

≤7 (3 + 4)

32 (43 · 2)

96 (73 · 3)

p = <0 · 0001

≥7 (4 + 3)

42 (56 · 7)

35 (26 · 7)

 

Staging data

≤T3a

44 (58·7)

64 (48·8)

P = <0·0005

>T3a

12 (16·0)

5 (3·8)

 

No Data available

19 (25·3)

62 (47·3)

 

ADT

Number

Mean (SD)

Estimate (95 % CI)

p

BMI

Yes

74

27 · 45 (4 · 19)

0 · 161 (−0 · 903 – 1 · 227)

0 · 7635

 

No

128

27 · 28 (3 · 31)

0 · 0

 

Age at Diagnosis

Yes

74

69 · 87 (7 · 95)

3 · 458 (0 · 931 – 5 · 986)

<0 · 0001

 

No

129

65 · 26 (7 · 70)

0 · 0

 
  1. CVD cardiovascular disease
  2. Total comorbidities included CVD together with diabetes, gout, acid reflux, neurological disorders, arthritis, psychological disorders, asthma and epilepsy
  3. All characteristics that showed a significant variation between the ADT and No ADT groups were subsequently corrected in the proceeding analysis, except for staging characteristics that had 25·3 % and 47·3 % of data not available between the ADT and No ADT groups respectively